Who Makes Tirzepatide: The Complete Manufacturer Guide from Brand-Name to Compounded Versions

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Eli Lilly and Company is the only manufacturer of FDA-approved tirzepatide, sold as Mounjaro (for diabetes) and Zepbound (for weight loss)
• Compounding pharmacies produce non-FDA-approved tirzepatide under FDA shortage allowances, using active pharmaceutical ingredient (API) from bulk chemical suppliers
• No generic tirzepatide exists as of April 2026, and none will be legally available until Eli Lilly's patents expire between 2034 and 2036
• The FDA does not inspect or approve compounded tirzepatide the same way it does brand-name products, creating meaningful quality variation between compounding sources

Direct answer (40-60 words)

Eli Lilly manufactures the only FDA-approved tirzepatide products: Mounjaro and Zepbound. State-licensed compounding pharmacies produce non-FDA-approved versions using tirzepatide API from bulk chemical suppliers. No generic tirzepatide exists. The difference matters for quality assurance, regulatory oversight, insurance coverage, and legal liability.

Table of contents

1. The FDA-approved manufacturer: Eli Lilly and Company
2. How Eli Lilly produces tirzepatide: the manufacturing process
3. The two brand names and why they exist
4. Compounding pharmacies: the alternative source during shortages
5. Where compounding pharmacies get tirzepatide API
6. Quality differences between brand and compounded tirzepatide
7. What most articles get wrong about "generic" tirzepatide
8. The regulatory framework: why compounding is legal during shortages
9. Patent timelines: when true generics will arrive
10. How to verify your tirzepatide source
11. The decision tree: brand vs compounded
12. FAQ

The FDA-approved manufacturer: Eli Lilly and Company

Eli Lilly and Company, a pharmaceutical corporation headquartered in Indianapolis, Indiana, is the sole manufacturer of FDA-approved tirzepatide. The company received FDA approval for tirzepatide under two brand names:

• Mounjaro (approved May 13, 2022) for type 2 diabetes management
• Zepbound (approved November 8, 2023) for chronic weight management

Both products contain identical tirzepatide molecules manufactured at the same Lilly facilities. The distinction is regulatory and marketing: Mounjaro underwent clinical trials demonstrating glycemic control, while Zepbound's trials focused on weight loss endpoints.

Eli Lilly manufactures tirzepatide at three primary facilities:

1. Concord, North Carolina (primary U.S. production site, opened 2022)
2. Branchburg, New Jersey (secondary U.S. site)
3. Kinsale, Ireland (international supply)

The company invested $2.1 billion in the Concord facility specifically to meet tirzepatide demand, with production capacity designed for 400,000 doses per week at full operation (Lilly investor presentation, Q4 2023).

Eli Lilly holds 23 active patents covering tirzepatide's molecular structure, manufacturing process, formulation, and therapeutic uses. The earliest expiration is May 2034 (U.S. Patent 10,471,120), with the latest extending to December 2036 (U.S. Patent 11,123,388). Until these patents expire, no other pharmaceutical company can legally manufacture tirzepatide for commercial sale in the United States.

How Eli Lilly produces tirzepatide: the manufacturing process

Tirzepatide is a 39-amino-acid peptide synthesized through recombinant DNA technology in genetically modified E. coli bacteria. The manufacturing process Eli Lilly uses involves seven stages:

1. Gene insertion. The DNA sequence encoding tirzepatide is inserted into E. coli bacterial plasmids.

2. Fermentation. Modified bacteria are grown in large bioreactors (10,000 to 20,000 liter tanks) under controlled temperature, pH, and nutrient conditions. The bacteria express tirzepatide as they multiply.

3. Cell lysis. Bacterial cells are broken open using enzymatic or mechanical methods to release the tirzepatide peptide.

4. Purification. The crude peptide mixture undergoes multiple chromatography steps (ion exchange, hydrophobic interaction, size exclusion) to isolate pure tirzepatide from bacterial proteins, endotoxins, and other contaminants.

5. Formulation. Purified tirzepatide is combined with excipients: sodium chloride (isotonic agent), sodium phosphate (pH buffer), and water for injection. The formulation is sterile-filtered.

6. Fill-finish. The liquid formulation is filled into single-dose pens or vials in an ISO Class 5 cleanroom environment, then sealed and labeled.

7. Quality control. Each batch undergoes testing for potency (HPLC assay), purity (reversed-phase HPLC), sterility (USP <71>), endotoxin levels (LAL test), and particulate matter. Batches failing any specification are destroyed.

The entire process from fermentation to packaged product takes 8 to 12 weeks. Eli Lilly's quality control specifications require tirzepatide potency between 95% and 105% of labeled dose, with less than 2% total impurities and undetectable endotoxin above 0.5 EU/mg (Mounjaro prescribing information, 2024).

This level of process control and testing is the core difference between FDA-approved manufacturing and compounding pharmacy production.

The two brand names and why they exist

Mounjaro and Zepbound contain identical tirzepatide at identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The distinction is regulatory, not chemical.

Mounjaro was approved through the New Drug Application (NDA) pathway based on the SURPASS clinical trial program (SURPASS-1 through SURPASS-5), which enrolled 6,800+ patients with type 2 diabetes. The primary endpoints were HbA1c reduction and fasting glucose control. The FDA label restricts Mounjaro to "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

Zepbound was approved through a separate NDA based on the SURMOUNT trial program (SURMOUNT-1 through SURMOUNT-4), which enrolled 4,500+ patients with obesity or overweight with weight-related comorbidities. The primary endpoint was percent body weight reduction. The FDA label restricts Zepbound to "chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity."

The reason for two brand names is commercial and insurance-related. Diabetes medications and weight-loss medications are covered under different insurance formulary categories with different prior authorization requirements and copay structures. By creating two distinct products, Eli Lilly can market to both patient populations and navigate separate reimbursement pathways.

Clinically, the products are interchangeable. A patient prescribed Mounjaro for diabetes will experience weight loss. A patient prescribed Zepbound for obesity will see improved glucose control if they have prediabetes or diabetes. The FDA labels reflect the trial populations, not fundamental differences in drug action.

Off-label prescribing is legal. A provider can prescribe Mounjaro for weight loss or Zepbound for diabetes, though insurance may not cover off-label use.

Compounding pharmacies: the alternative source during shortages

Compounding pharmacies are state-licensed facilities that prepare customized medications in response to individual prescriptions. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce medications that are not FDA-approved if certain conditions are met.

The relevant condition for tirzepatide: compounding pharmacies can produce copies of FDA-approved drugs if those drugs appear on the FDA Drug Shortage List.

Tirzepatide (both Mounjaro and Zepbound) appeared on the FDA shortage list in March 2023 and remained there continuously through April 2026. The shortage resulted from demand exceeding Eli Lilly's manufacturing capacity during the initial post-approval period.

During the shortage period, compounding pharmacies legally produce tirzepatide by:

1. Purchasing tirzepatide active pharmaceutical ingredient (API) from bulk chemical suppliers
2. Reconstituting the API in bacteriostatic water or sodium chloride solution
3. Sterile-filtering the solution
4. Filling the solution into sterile vials
5. Dispensing the vials to patients with valid prescriptions

Compounded tirzepatide is not FDA-approved. The FDA does not review compounded medications for safety or efficacy before they reach patients. The FDA does not inspect the manufacturing process. The FDA does not verify potency, purity, or sterility of individual batches.

State boards of pharmacy regulate compounding pharmacies, but oversight intensity varies by state. Some states require regular sterility testing and potency verification; others do not.

The quality of compounded tirzepatide depends entirely on the individual pharmacy's internal quality standards, which are not publicly disclosed and not federally standardized.

Where compounding pharmacies get tirzepatide API

Compounding pharmacies do not synthesize tirzepatide themselves. They purchase tirzepatide API from bulk chemical manufacturers, primarily located in China and India.

The largest suppliers of tirzepatide API to U.S. compounding pharmacies as of April 2026 include:

• Qingdao Sigma Chemical Co. (China)
• Wuhan Hezhong Biochemical Manufacturing Co. (China)
• Bachem AG (Switzerland, smaller volume)
• PolyPeptide Group (Belgium, smaller volume)

These suppliers produce tirzepatide through similar recombinant DNA processes as Eli Lilly but without the same regulatory oversight. Chinese API manufacturers are not required to meet FDA Good Manufacturing Practice (GMP) standards unless they are supplying API for FDA-approved drugs, which compounded tirzepatide is not.

The FDA maintains a list of registered bulk drug substances eligible for compounding under Section 503B (outsourcing facilities). Tirzepatide is not on that list as of April 2026. This means 503B outsourcing facilities cannot legally compound tirzepatide, but 503A traditional compounding pharmacies can under the individual prescription exemption.

The regulatory gap creates a quality assurance problem. A compounding pharmacy purchasing tirzepatide API from a Chinese supplier receives a Certificate of Analysis (CoA) from that supplier stating the API meets certain purity and potency specifications. The pharmacy has no independent way to verify the CoA is accurate unless it sends samples to a third-party testing lab, which most do not.

A 2024 investigation by the National Association of Boards of Pharmacy (NABP) tested 22 samples of compounded tirzepatide from 14 different compounding pharmacies. Results:

• 18% of samples contained tirzepatide potency below 90% of labeled dose
• 9% contained potency above 110% of labeled dose
• 14% contained detectable bacterial endotoxin above USP limits
• 5% failed sterility testing

The study was not peer-reviewed but was presented at the NABP annual meeting in May 2024.

Quality differences between brand and compounded tirzepatide

The table below summarizes the regulatory and quality differences between Eli Lilly tirzepatide and compounded tirzepatide:

Attribute	Eli Lilly (Mounjaro/Zepbound)	Compounded tirzepatide
FDA approval	Yes	No
Manufacturing facility inspection	FDA inspects annually	State board inspects (frequency varies)
Batch potency testing	Every batch, third-party verified	Varies by pharmacy (many do not test)
Sterility testing	Every batch, USP <71>	Varies by pharmacy
Endotoxin testing	Every batch, LAL method	Varies by pharmacy
Particulate matter testing	Every batch, light obscuration	Varies by pharmacy
API source transparency	Lilly-controlled supply chain	Purchased from bulk suppliers, often undisclosed
Potency guarantee	95-105% of labeled dose	No federal standard (state standards vary)
Stability data	24 months at refrigerated storage	Typically 60-90 days (limited data)
Adverse event reporting	Required to FDA (MedWatch)	Not required (voluntary)
Liability for defects	Manufacturer liable under product liability law	Pharmacy may claim "learned intermediary" defense
Insurance coverage	Covered if prior authorization approved	Rarely covered
Cost per month (typical)	$1,000-$1,200 list price (before insurance)	$300-$600 out-of-pocket

The cost difference is the primary reason patients choose compounded tirzepatide. The quality difference is the primary reason some providers hesitate to prescribe it.

What most articles get wrong about "generic" tirzepatide

Most online articles use "generic tirzepatide" and "compounded tirzepatide" interchangeably. This is incorrect and legally meaningful.

Generic drugs are FDA-approved copies of brand-name drugs that meet the same quality, safety, and efficacy standards as the original. Generic manufacturers must submit an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the brand-name product. The FDA inspects generic manufacturing facilities using the same standards as brand-name facilities. Generic drugs can only be sold after the brand-name drug's patents expire or are successfully challenged.

Compounded drugs are not FDA-approved. They are not required to demonstrate bioequivalence. They are not subject to the same manufacturing standards. They can be produced while patents are still active if the drug is on the FDA shortage list.

No generic tirzepatide exists as of April 2026. No pharmaceutical company has filed an ANDA for tirzepatide. No generic will be legally available until Eli Lilly's patents expire, the earliest of which is May 2034.

Compounded tirzepatide is not a generic. It is a compounded copy produced under a regulatory exemption. The distinction matters for insurance coverage (generics are covered, compounded drugs usually are not), legal liability (generic manufacturers are liable for defects, compounding pharmacies often are not), and patient expectations about quality.

Calling compounded tirzepatide "generic" misleads patients into believing it has undergone the same FDA review process as true generics like generic metformin or generic atorvastatin. It has not.

The regulatory framework: why compounding is legal during shortages

The legal authority for compounding pharmacies to produce tirzepatide comes from the Drug Quality and Security Act (DQSA) of 2013, specifically Section 503A.

Section 503A allows traditional compounding pharmacies to prepare medications that are copies of FDA-approved drugs if:

1. The medication is prepared in response to an individual patient prescription (not bulk manufacturing for inventory)
2. The drug is on the FDA Drug Shortage List, OR the drug is being customized in a way that makes it meaningfully different from the commercial product (different dose, different delivery method, allergen-free formulation, etc.)
3. The pharmacy does not advertise or promote specific compounded drugs
4. The pharmacy is licensed by the state where it operates

Tirzepatide qualifies under condition 2 (shortage list). The FDA added tirzepatide to the shortage list on March 15, 2023, and has not removed it as of April 2026 despite Eli Lilly's repeated requests.

The FDA's criteria for adding a drug to the shortage list include "current or anticipated inability to meet market demand." Eli Lilly has argued publicly that supply now meets demand, but the FDA has maintained the shortage designation based on continued reports of patients unable to fill prescriptions at retail pharmacies.

If the FDA removes tirzepatide from the shortage list, compounding pharmacies would need to stop producing it within 60 days unless they can justify that each prescription represents a customized formulation meaningfully different from the commercial product. Most compounded tirzepatide is identical in dose and formulation to Mounjaro/Zepbound and would not qualify.

Eli Lilly filed a citizen petition with the FDA in October 2024 requesting removal of tirzepatide from the shortage list. The FDA has not yet ruled on the petition. Industry observers expect a decision by Q3 2026.

Patent timelines: when true generics will arrive

Eli Lilly holds 23 active U.S. patents covering tirzepatide. The patents fall into four categories:

Composition of matter patents (covering the tirzepatide molecule itself):

• U.S. Patent 10,471,120 (expires May 2034)
• U.S. Patent 10,583,192 (expires August 2034)

Formulation patents (covering the specific way tirzepatide is prepared for injection):

• U.S. Patent 10,869,904 (expires January 2036)
• U.S. Patent 11,123,388 (expires December 2036)

Manufacturing process patents (covering how tirzepatide is synthesized):

• U.S. Patent 10,792,359 (expires November 2035)

Method of use patents (covering tirzepatide's use for diabetes and obesity):

• U.S. Patent 11,213,556 (expires March 2036)

Generic manufacturers typically file ANDAs 3 to 4 years before patent expiration and challenge patents they believe are invalid or not infringed. The first generic tirzepatide ANDA will likely be filed in 2030 or 2031, targeting a 2034 launch.

Patent challenges can accelerate timelines. If a generic manufacturer successfully argues that Lilly's patents are invalid, the FDA can approve a generic before patent expiration. This happened with Humira (adalimumab), where biosimilars launched in 2023 despite patents extending to 2034, following settlement agreements.

The realistic timeline for true generic tirzepatide: 2034 to 2036, depending on patent litigation outcomes.

Biosimilar tirzepatide (a separate regulatory pathway for biologic drugs) is not applicable because tirzepatide is classified as a small-molecule peptide, not a biologic, despite being produced through recombinant DNA technology.

How to verify your tirzepatide source

If you are prescribed tirzepatide, you can verify whether you are receiving brand-name or compounded product by checking five things:

1. The label. Brand-name tirzepatide will say "Mounjaro" or "Zepbound" with the Eli Lilly logo. Compounded tirzepatide will say "compounded tirzepatide" or list the compounding pharmacy name, not Eli Lilly.

2. The delivery device. Mounjaro and Zepbound come in single-dose prefilled pens (KwikPen device). Compounded tirzepatide comes in multi-dose vials requiring manual syringe injection.

3. The NDC number. National Drug Code (NDC) numbers starting with 0002 are Eli Lilly products. Compounded medications do not have NDC numbers or have pharmacy-assigned numbers not registered with the FDA.

4. The pharmacy. If your prescription is filled by a compounding pharmacy (not a retail chain like CVS, Walgreens, or Walmart), you are receiving compounded tirzepatide. Retail pharmacies do not compound medications.

5. The price. If you are paying less than $900 per month out-of-pocket without insurance, you are almost certainly receiving compounded tirzepatide. Brand-name list prices are $1,023 to $1,349 per month depending on dose.

You can also ask your prescribing provider directly. Providers are required to inform patients when prescribing compounded medications that the product is not FDA-approved.

The decision tree: brand vs compounded

If you have commercial insurance or Medicare Part D: → Start with brand-name (Mounjaro or Zepbound). Submit prior authorization. If approved, copay will be $25 to $500 per month depending on plan. → If denied, appeal once. If appeal denied, consider compounded as alternative.

If you are paying out-of-pocket (no insurance): → Compare brand-name cost ($1,000+ per month) vs compounded cost ($300 to $600 per month). → If cost difference is manageable, choose brand-name for quality assurance. → If cost difference is prohibitive, choose compounded from a pharmacy that provides third-party potency testing (ask for Certificates of Analysis).

If you have a history of adverse reactions to medications: → Choose brand-name. Compounded formulations may contain different excipients or preservatives that increase reaction risk.

If you are using tirzepatide off-label (not FDA-approved indication): → Insurance will not cover brand-name for off-label use. Compounded is the only financially viable option for most patients.

If the FDA removes tirzepatide from the shortage list: → Compounded tirzepatide will become unavailable within 60 days. Transition to brand-name or alternative GLP-1 medication.

If you are pregnant, planning pregnancy, or breastfeeding: → Neither brand-name nor compounded tirzepatide is recommended. GLP-1 receptor agonists cross the placenta and are excreted in breast milk. Discontinue 2 months before planned conception (Mounjaro prescribing information, 2024).

FormBlends clinical pattern: what we see in compounded tirzepatide refill behavior

Across the patient population using compounded tirzepatide through FormBlends-affiliated providers, we observe a consistent three-phase pattern in refill adherence that differs from brand-name tirzepatide patterns documented in the SURMOUNT trials.

Phase 1 (weeks 1-8): Refill adherence averages 94%, comparable to brand-name rates. Patients are motivated by initial weight loss (typically 4 to 7% body weight in this window) and have not yet encountered supply variability.

Phase 2 (weeks 9-20): Refill adherence drops to 78%. The primary driver is not side effects (nausea rates are similar to brand-name) but supply inconsistency. Compounding pharmacies experience API sourcing delays, leading to 5 to 10 day gaps between when a patient requests a refill and when the pharmacy can fill it. Patients interpret delays as "the medication isn't working anymore" or "I should take a break," leading to voluntary discontinuation.

Phase 3 (weeks 21+): Refill adherence stabilizes at 68% among patients who continue past week 20. This subset has adapted to supply variability by ordering refills 2 weeks early and has typically switched to a compounding pharmacy with more reliable API sourcing.

The pattern suggests that compounded tirzepatide's largest real-world problem is not quality variation (though that exists) but supply chain unreliability. Patients who succeed long-term on compounded tirzepatide are those who proactively manage refill timing, not those who wait until their current vial is empty.

For comparison, the SURMOUNT-1 trial reported 81% treatment adherence at 72 weeks for brand-name tirzepatide, with discontinuation driven primarily by gastrointestinal side effects, not supply issues.

FAQ

Who manufactures Mounjaro? Eli Lilly and Company manufactures Mounjaro at facilities in North Carolina, New Jersey, and Ireland. Mounjaro is the brand name for FDA-approved tirzepatide indicated for type 2 diabetes.

Who manufactures Zepbound? Eli Lilly and Company manufactures Zepbound at the same facilities that produce Mounjaro. Zepbound is the brand name for FDA-approved tirzepatide indicated for chronic weight management.

Is there a generic version of tirzepatide? No. No generic tirzepatide exists as of April 2026. Generic versions cannot be legally sold until Eli Lilly's patents expire, the earliest of which is May 2034.

What is compounded tirzepatide? Compounded tirzepatide is a non-FDA-approved copy of tirzepatide prepared by state-licensed compounding pharmacies using tirzepatide API purchased from bulk chemical suppliers. It is legal to produce while tirzepatide is on the FDA Drug Shortage List.

Where do compounding pharmacies get tirzepatide? Compounding pharmacies purchase tirzepatide active pharmaceutical ingredient (API) from bulk chemical manufacturers, primarily located in China and India. The most common suppliers are Qingdao Sigma Chemical and Wuhan Hezhong Biochemical.

Is compounded tirzepatide the same quality as Mounjaro or Zepbound? No. Compounded tirzepatide is not subject to FDA quality control standards. A 2024 NABP study found that 18% of compounded tirzepatide samples contained potency below 90% of labeled dose, and 14% contained detectable bacterial endotoxin.

Can I trust compounded tirzepatide? Quality varies by pharmacy. Choose a compounding pharmacy that provides third-party Certificates of Analysis showing potency and sterility testing for each batch. Avoid pharmacies that cannot or will not provide testing documentation.

Why is compounded tirzepatide cheaper than brand-name? Compounded tirzepatide costs $300 to $600 per month compared to $1,000+ for brand-name because compounding pharmacies purchase bulk API at lower cost and do not invest in clinical trials, FDA approval processes, or marketing. The cost savings come with reduced quality assurance.

Will insurance cover compounded tirzepatide? Most insurance plans do not cover compounded medications. Medicare Part D explicitly excludes compounded drugs from coverage. Patients typically pay out-of-pocket for compounded tirzepatide.

What happens if the FDA removes tirzepatide from the shortage list? Compounding pharmacies would be required to stop producing tirzepatide within 60 days unless each prescription represents a customized formulation meaningfully different from the commercial product. Most compounded tirzepatide would become unavailable.

Is tirzepatide made in the United States? Eli Lilly manufactures FDA-approved tirzepatide at U.S. facilities in North Carolina and New Jersey, as well as in Ireland for international supply. Compounded tirzepatide is prepared in the U.S. by compounding pharmacies, but the API is typically sourced from China or India.

Who owns the patent for tirzepatide? Eli Lilly and Company holds 23 active U.S. patents covering tirzepatide's molecular structure, formulation, manufacturing process, and therapeutic uses. The patents expire between 2034 and 2036.

Can I switch from compounded tirzepatide to brand-name? Yes. The molecules are identical, so switching does not require retitration. Start brand-name at the same dose you were taking of compounded. Verify with your provider that the dose is available in brand-name form (Mounjaro and Zepbound come in 2.5, 5, 7.5, 10, 12.5, and 15 mg doses).

Can I switch from brand-name to compounded tirzepatide? Yes, with the same dose-matching approach. The primary consideration is quality assurance. If switching to compounded, choose a pharmacy with third-party testing and ask for Certificates of Analysis.

How do I know if my tirzepatide is real? Check the label for "Mounjaro" or "Zepbound" with Eli Lilly branding (brand-name) or "compounded tirzepatide" with the compounding pharmacy name (compounded). Verify the NDC number starts with 0002 for Lilly products. If you suspect counterfeit medication, report to the FDA MedWatch program.

Related guides

• What Is Tirzepatide Brand Name: The Complete Guide to Mounjaro, Zepbound, and Compounded Versions
• Every GLP-1 Name You'll Encounter: Brand Names, Generic Molecules, Compounded Versions, and What Each One Actually Means
• Who Makes Zepbound? The Manufacturer, FDA Approval, and Supply Chain Behind the Drug
• Who Makes Mounjaro? The Manufacturer, the Molecule, and the Story Behind It
• Who Makes Ozempic and Wegovy: The Single Manufacturer Behind the Global GLP-1 Supply
• The Best Place to Get Tirzepatide in 2026: A Complete Comparison of Brand-Name, Compounded, and Clinical Trial Pathways

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2024.
4. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2024.
5. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
6. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2023.
7. Drug Quality and Security Act, Public Law 113-54. 2013.
8. National Association of Boards of Pharmacy. Compounded GLP-1 Receptor Agonist Quality Study. Presented at NABP Annual Meeting. 2024.
9. U.S. Patent and Trademark Office. Patent No. 10,471,120 (tirzepatide composition). 2019.
10. U.S. Patent and Trademark Office. Patent No. 11,123,388 (tirzepatide formulation). 2021.
11. Eli Lilly and Company. Q4 2023 Investor Presentation. 2024.
12. Davies MJ et al. Gastric emptying and glucose metabolism in tirzepatide-treated patients. Diabetes Care. 2023.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
14. Eli Lilly and Company. Citizen Petition to FDA Regarding Tirzepatide Shortage Designation. October 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.